Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD) - LARVOL DELTA

Projected epidemiological impact of lowering the adult pneumococcal vaccination age from 60 to 50 years in Germany. (PubMed, Hum Vaccin Immunother) - "When vaccinating ages ≥60 and ≥50 with V116, the projected incidence of IPD in year 10 declined to 22.1 and 20.5 per 100,000, respectively, and when using PCV20 in the same conditions, incidence was 23.0 and 21.8, respectively. In summary, lowering the adult vaccination age enhanced the epidemiological impact of pneumococcal vaccination in Germany, with V116 showing the greatest overall reductions in disease."

Journal • Infectious Disease • Pneumococcal Infections • Pneumonia • Respiratory Diseases

ACQUIVAS: Acquired Immunodeficiency in ANCA Associated Vasculitis (clinicaltrials.gov) - P2 | N=114 | Completed | Sponsor: Cambridge University Hospitals NHS Foundation Trust | Unknown status ➔ Completed

Trial completion • ANCA Vasculitis • Human Immunodeficiency Virus • Vasculitis

TACmono LT (clinicaltrialsregister.eu) - P3/4 | N=66 | Recruiting | Sponsor: Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC) | Not yet recruiting ➔ Recruiting

Enrollment open • Transplantation

Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients (clinicaltrials.gov) - P2 | N=75 | Recruiting | Sponsor: University of California, Davis | Trial completion date: Jul 2026 ➔ Jul 2027 | Trial primary completion date: Jul 2026 ➔ Jul 2027

Trial completion date • Trial primary completion date • Infectious Disease • Pneumococcal Infections

Adult immunization. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Hepatitis B • Herpes Zoster • Infectious Disease • Inflammation • Influenza • Measles • Meningococcal Infections • Pertussis • Pneumococcal Infections • Respiratory Diseases • Respiratory Syncytial Virus Infections • Tetanus • Varicella Zoster

Comparison chart: Some vaccines for adults. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Hepatitis B • Infectious Disease • Inflammation • Influenza • Measles • Meningococcal Infections • Pertussis • Pneumococcal Infections • Respiratory Diseases • Respiratory Syncytial Virus Infections • Tetanus

Invasive pneumococcal disease in Latin America: serotype distribution and vaccine coverage among adults in Mexico, Brazil, and Argentina. (PubMed, Vaccine) - "PCV21 offers substantially broader potential coverage for adult IPD than PCV20 and earlier-generation PCVs in Argentina, Brazil, and Mexico. If incorporated into adult immunization programs with sufficient uptake, PCV21 could meaningfully reduce IPD burden."

Journal • Infectious Disease • Pediatrics • Pneumococcal Infections • Pneumonia

Vaccine Responses in Patients With B Cell Malignancies (clinicaltrials.gov) - P4 | N=350 | Recruiting | Sponsor: National Heart, Lung, and Blood Institute (NHLBI) | Trial completion date: Aug 2026 ➔ Nov 2036 | Trial primary completion date: Aug 2026 ➔ Nov 2036

Trial completion date • Trial primary completion date • Chronic Lymphocytic Leukemia • Hematological Malignancies • Lymphoma • Oncology • BCL2

Vaccine Responses in Patients With B Cell Malignancies (clinicaltrials.gov) - P4 | N=350 | Recruiting | Sponsor: National Heart, Lung, and Blood Institute (NHLBI) | N=500 ➔ 350

Enrollment change • Chronic Lymphocytic Leukemia • Hematological Malignancies • Lymphoma • Oncology • BCL2

SPLENEVAC-2: Revaccination With PPS23 Boosted or Not by PCV13 in Splenectomised Patients. (clinicaltrials.gov) - P2 | N=39 | Completed | Sponsor: Assistance Publique - Hpitaux de Paris | Active, not recruiting ➔ Completed

Trial completion

A phase 3, randomized study to evaluate the safety, tolerability, and immunogenicity of V116 in children and adolescents with increased risk of pneumococcal disease (STRIDE-13). (PubMed, Hum Vaccin Immunother) - "In children and adolescents aged 2 to <18 y with certain medical conditions, V116 is well tolerated and immunogenic. These findings support the use of V116 to broaden pneumococcal serotype coverage in populations at increased risk of pneumococcal disease."

Clinical • Journal • P3 data • Diabetes • Hepatology • Infectious Disease • Metabolic Disorders • Nephrology • Pneumococcal Infections

HEMATOVAC: Clinical Trial Assessing the Immunogenicity of an Anti-pneumococcal Vaccination Strategy (PCV13+PPV23 Versus PREVENAR20) in Adult Patients Treated for a Lymphoma (clinicaltrials.gov) - P4 | N=160 | Recruiting | Sponsor: Poitiers University Hospital | Trial completion date: Nov 2027 ➔ Jun 2029 | Trial primary completion date: Dec 2026 ➔ Jun 2028

Trial completion date • Trial primary completion date • B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Infectious Disease • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Pneumococcal Infections • Pneumonia

Lenalidomide and Vaccine Therapy in Treating Patients With Early-Stage Asymptomatic Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (clinicaltrials.gov) - P2 | N=49 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: May 2026 ➔ May 2027

Trial completion date • Chronic Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Small Lymphocytic Lymphoma

Epidemiological impact of a 20- or 21-valent pneumococcal conjugate vaccine in the Japan adult population: insights from a dynamic transmission model. (PubMed, Expert Rev Vaccines) - "Further gains were projected when expanded recommendations were combined with increased vaccination coverage (from 39.1% to 53.2%-93.8%), with IPD reductions of 2.6%-6.5% for PCV20 and 8.5%-18.2% for V116. Results highlight the value of broader age recommendations and higher vaccine uptake in Japan and indicate that V116 can achieve greater reductions in pneumococcal disease burden than PCV20 or PPSV23, supporting consideration of V116 for adult vaccination in Japan."

Journal • Infectious Disease • Pediatrics • Pneumococcal Infections

Economic Evaluation of PCV21 Use in Populations with Increasing Serotype 4 Invasive Pneumococcal Disease in the US: An Attributable Fraction Threshold Analysis. (PubMed, Infect Dis Ther) - "For populations experiencing moderate increases in the proportion of ST4 (i.e., < 30%), PCV21 may offer health and economic benefits over PCV20 for US adults aged 19-64 years with underlying medical conditions. However, in populations with ≥ 30% ST4, ST4-containing vaccines should be used as per ACIP guidance."

HEOR • Journal • Infectious Disease • Pneumococcal Infections

REANALYSING PNEUMOCOCCAL ANTIBODY RESPONSES IN DIAGNOSIS OF PRIMARY ANTIBODY DEFICIENCY IN ADULTS (ISPPD 2026) - "PRP scores were calculated using post-Pneumovax antibody response data from 120 healthy Danish adults between ages of 16-65 years (2)...doi: 10.1007/s10875-025-01915-w 3. https://esid.org/wp-content/uploads/2023/09/ESID-Clin-Crit_omim_orpha_hpo_11_2019fin.pdf"

Clinical • Immunology • Infectious Disease • Pneumococcal Infections • Primary Immunodeficiency

Care Gaps in Revaccination of Non-Hematopoietic Stem Cell Transplant Childhood Cancer Survivors (ASPHO 2026) - "The one provider who routinely revaccinates does so after assessing titers, most often giving Pneumovax, while only one additional provider routinely checks titers and 1/10 sometimes check titers depending on therapy received or delayed lymphocyte recovery...Blinatumomab and Rituximab)... There is no consensus or standard for revaccinating non-HSCT childhood cancer survivors at HDVCH, a population particularly at risk given inadequate protection against vaccine preventable disease and the national growing threat to heard immunity. Additionally, the rise in immunotherapy (ex. Blinatumomab) and immune modulators as primary therapy requires further research on the impact of these treatments to vaccine titers and post therapy vaccine efficacy and timing."

Clinical • Bone Marrow Transplantation • Hematological Malignancies • Infectious Disease • Measles • Mumps • Transplantation • Varicella Zoster

Clinical Trial of PCV24 in Adults Aged ≥18 Years (clinicaltrials.gov) - P1/2 | N=385 | Completed | Sponsor: Sinovac Life Sciences Co., Ltd.

New P1/2 trial • Infectious Disease • Pneumococcal Infections

Characterization of the B1 Cell Repertoire in Sickle Cell Disease Pre- and Post-Pneumococcal Vaccination (IMMUNOLOGY 2026) - "CD5+B1a cells produce natural antibodies that provide immediate protection against pneumococcal infections, whereas CD5-B1b cells produce protective adaptive antibodies in response to pneumococcal vaccination. We examined the peritoneal and splenic CD5+B1a and CD5-B1b cell repertoires pre- and post-vaccination with Pneumovax23 (PPSV23) in mice with sickle cell disease (Townes model) and compared them with healthy controls... Our results revealed significant differences in the pre- and post-PPSV23 vaccination repertoire of B1 cells in SCD mice compared to healthy mice, offering insights into the effectiveness of pneumococcal vaccination in SCD. These results provide a rationale for optimizing vaccine strategies and developing targeted immunotherapies to enhance immune protection in patients with SCD."

Pneumococcal vaccines • Genetic Disorders • Hematological Disorders • Infectious Disease • Pneumococcal Infections • Pneumonia • Sickle Cell Disease • CD5

Pneumococcal Pneumonia Vaccine Series (PCV20 and PPSV23) in Patients With Chronic Lymphocytic Leukemia Associated Immunodeficiency, PROTECT CLL Trial (clinicaltrials.gov) - P2 | N=61 | Recruiting | Sponsor: University of Utah | Trial primary completion date: Jun 2026 ➔ Mar 2027

Trial primary completion date • Chronic Lymphocytic Leukemia • Hematological Malignancies • Infectious Disease • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Pneumococcal Infections • Pneumonia • Respiratory Diseases • Small Lymphocytic Lymphoma

With Gardasil demand shortfall in China, Merck and Zhifei adjust their partnership (Fierce Pharma) - "The companies have agreed to remove minimum purchase commitments and use a rolling, demand-based supply model for the three Merck vaccines that Zhifei distributes in China. In addition to Gardasil, Zhifei distributes rotavirus shot, RotaTeq, and pneumococcal vaccine Pneumovax 23...The companies were operating under a multiyear deal, which specified a total procurement commitment of 97.9 billion Chinese yuan ($14.2 billion), running from 2023 to 2026. The new arrangement will run until the end of 2028."

Commercial • Anal Carcinoma • Cervical Cancer • Pneumococcal Infections • Vaginal Cancer • Vulvar Cancer

AN EVALUATION OF COMPLIANCE WITH A VACCINATION PROGRAMME FOR PATIENTS WHO HAVE UNDERGONE ALLOGENEIC STEM CELL TRANSPLANTATION OR CAR T-CELL THERAPY (EBMT 2026) - "These errors were classified into nine categories, as shown in Figure 1.The most common reason for non-compliance was booster doses given instead of the primary vaccine(s) (n=44), this included COVID-19 boosters given instead of primary doses (n=30) and Pneumovax 23® (designed to be given as a booster) being given instead of Prevenar13® (n=13)... This retrospective service evaluation has highlighted significant non-compliance with the vaccination schedule post AlloSCT and CAR-T, with 58.5% of patients identified as non-compliant. Reasons were not directly investigated but are likely to be multifactorial e.g. delayed or missing vaccine paperwork, unfamiliarity with the procedure amongst GPs or vaccine unavailability. The non-compliance issues identified could potentially lead to inadequate vaccine responses, leaving patients vulnerable to vaccine-preventable infections."

CAR T-Cell Therapy • Clinical • Compliance • Graft versus Host Disease • Hematological Disorders • Herpes Zoster • Immunology • Infectious Disease • Novel Coronavirus Disease • Transplantation • Varicella Zoster

Serotype Distribution among Streptococcus pneumoniae Isolates in Puerto Rico. (PubMed, P R Health Sci J) - "Our findings highlight the importance of continuous surveillance to detect early serotype changes, ongoing vaccination to avoid preventable infections and complications, and pursuing new higher-valency vaccines with broad serotype coverage to address the evolving pneumococcal disease epidemiology."

Journal • Observational data • Infectious Disease • Pneumococcal Infections • Pneumonia

Expanding the phenotypic and immunological landscape of Alazami syndrome: Evidence from seven new patients with LARP7 gene variants. (PubMed, Eur J Pediatr) - "A functional assay of B lymphocyte response was performed in one family, demonstrating impaired Streptococcus pneumoniae IgG antibody production following Pneumovax vaccination in the male patient, while his female sibling mounted an adequate response. In conclusion, the disease has a wide range of symptoms, which vary greatly among the affected patients. Our study expanded the clinical and molecular spectrum of the disorder and highlighted immunodeficiency as an underrecognized disease feature, potentially with a male sex predilection."

Journal • CNS Disorders • Dental Disorders • Developmental Disorders • Immunology • Infectious Disease • Mental Retardation • Pneumococcal Infections • Pneumonia • Primary Immunodeficiency • Psychiatry

4304 - The Pneumovax 23 Vaccine is Going Away: What Now: Update on Tools for Diagnosing Immunodeficiencies (AAAAI 2026) - "The landscape of pneumococcal vaccines is shifting, with the phase-out of Pneumovax 23 and increasing use of Prevnar 20/21. This session will also prepare you to recognize these diseases and prepare your practice for the risks and complications associated with these infections. Learning Objectives: - Explain guidelines on diagnostic vaccination in the evaluation of immunodeficiency- Describe how immunomodulatory medications affect vaccine response- Discuss vaccine preventable diseases in the era of declining herd immunity CME: 1.25 CE: 1.25 Participation: 1.25"

Immunology • Infectious Disease • Pneumococcal Infections • Primary Immunodeficiency